Health status of clients receiving methadone maintenance treatment using the SF-36 health survey questionnaire

Drug and Alcohol Review

Volumn 23, Issue 3, 2004, Pages 273-280

  Deering, Daryle E ^a   Frampton, Christopher M A ^a   Horn, Jacqueline ^a   Sellman, J Douglas ^a   Adamson, Simon J ^a   Potiki, Tuari L ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Ngai Tahu Development   (New Zealand)

Author keywords

Alcohol and drug; Health status; Methadone treatment; SF 36

Indexed keywords

METHADONE;

ADULT; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; FEMALE; HEALTH STATUS; HEALTH SURVEY; HUMAN; MALE; MIDDLE AGED; NEW ZEALAND; NONPARAMETRIC TEST; REVIEW; SOCIOECONOMICS;

ADULT; CHI-SQUARE DISTRIBUTION; FEMALE; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; METHADONE; MIDDLE AGED; NEW ZEALAND; SOCIOECONOMIC FACTORS; STATISTICS, NONPARAMETRIC;

EID: 4644344714     PISSN: 09595236     EISSN: None     Source Type: Journal    
DOI: 10.1080/09595230412331289428     Document Type: Review

References (38)

1. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence [seminar]. Lancet 1999;353:221-6.
2. Ball JC, Ross A. The effectiveness of methadone maintenance treatment: patients, programmes, services and outcomes. New York: Springer-Verlag, 1991.
3. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689-95.
4. Rounsaville BJ, Kleber HD. Untreated opiate addicts. How do they differ from those seeking treatment? Arch Gen Psychiatry 1985;42:1072-7.
5. Darke S, Swift W, Hall W. Prevalence, severity and correlates of psychological morbidity among methadone maintenance clients. Addiction 1994;89:211-17.
6. Rounsaville BJ, Weissman MM, Kleber H, Wilber C. Heterogeneity of psychiatric diagnosis in treated opiate addicts. Arch Gen Psychiatry 1982;39:161-6.
7. Gerstein DR, Harwood HJ, eds. Treating drug problems, Vol. 1: a study of the evolution, financing and effectiveness of public and private drug treatment systems. Washington DC: Institute of Medicine, National Academy Press, 1990:136-52.
8. Bell J. Delivering effective methadone treatment. In: Ward J, Mattick RP, Hall W, eds. Opioid maintenance treatment and other opioid replacement therapies. London: Harwood Academic Publishers, 1998:161-75.
9. Kemp R, Miller J, Lungley S, Baker M. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. NZ Med J 1998;111:50-3.
10. Chetwynd J, Brunton C, Plumridge E, Baldwin D. Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme. NZ Med J 1995;108:364-6.
11. Hall W. Perfectionism in the therapeutic appraisal of methadone maintenance [Editorial]. Addiction 1993;88:1181-2.
12. McLellan AT, Kushner H, Metzger D et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992;9:199-213.
13. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: the Opiate Treatment Index. Br J Addict 1992;87:733-42.
14. Marsden J, Gossop M, Stewart D et al. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction 1998;93:1857-68.
15. Sanderson K, Andrews G. Prevalence and severity of mental health-related disability and relationship to diagnosis. Psychiatr Serv 2002;53:80-6.
16. McHorney CA, Ware JE, Raczek AE. The MOS 36-item short-form health survey: II Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1992;30:475-83.
17. Ware JE, Snow KK, Kosinski, M, Gandek B. SF-36 health survey. Manual and interpretation guide. Boston, MA: The Health Institute, 1993.
18. Ministry of Health. Taking the pulse. The 1996/97 New Zealand health survey. Wellington: Ministry of Health, 1999.
19. Scott KM, Tobias MI, Sarfati D, Haslett SJ. SF-36 health survey reliability, validity and norms for New Zealand. Aust NZ J Public Health 1999;23:401-6.
20. Volk RJ, Cantor SB, Steinbauer JR, Cass AR. Alcohol use disorders, consumption patterns, and health-related quality of life of primary care patients. Alcohol Clin Exp Res 1997;21:899-905.
21. Rooney S, Freyne A, Kelly G, O'Connor J. Differences in the quality of life of two groups of drug users. Ir J Psych Med 2002;19:55-9.
22. White JM, Danz C, Kneebone J, La Vincente SF, New-combe DA, Ali RL. Relationship between LAAM-methadone preference and treatment outcomes. Drug Alcohol Depend 2002;66:295-301.
23. Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. Br Med J 1998;317:13-18.
24. Ryan CF, White JM. Health status at entry to methadone maintenance treatment using the SF-36 health survey questionnaire. Addiction 1996;91:39-45.
25. White JM, Ryan CF, Ali RL. Use of the SF-36 to monitor improvements in the health of methadone maintenance participants. In: Harris I, ed. Problems of drug dependence. Rockville: NIDA Research Monograph, 1996:164.
26. Torrens M, Luis S, Martinez A, Castillo C, Domingo-Salvany A, Alonso J. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction 1997;92:707-16.
27. Mackinnon S, Paton-Simpson G. Routine outcome measurement in methadone maintenance - feasibility and potential benefits. CIRU report. Auckland: Regional Alcohol and Drug Services Clinical Information and Research Unit, 1999.
28. Broughton J. Being Maori. NZ Med J 1993;106:506-8.
29. Sobell LC, Sobell MB. Timeline followback users guide: a calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation, 1996.
30. Fals-Stewart W, O'Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of psychoactive substance use by drug abusing patients: psychometric properties. J Consult Clin Psychol 2000;64:134-44.
31. MacEwan I. Upper limits for responsible drinking. ALAC Report of the Working Party on Upper Limits for Responsible Drinking. Wellington: Alcohol Advisory Council of New Zealand, 1995.
32. Sullivan PF, Builik CM. Mood disorders. In: Ellis PM, Collings SC, eds. Mental Health in New Zealand from a Public Health Perspective. Wellington: Ministry of Health, 1997:267-84.
33. Bushnell J. Anxiety disorders. In: Ellis PM, Collings SC, eds. Mental health in New Zealand from a public health perspective. Wellington: Ministry of Health, 1997:285-93.
34. Darke S, Swift W, Hall W, Ross M. Drug use, HIV risktaking and psychosocial correlates of benzodiazepine use among methadone maintenance clients. Drug Alcohol Depend 1993;34:67-70.
35. Darke S. The effectiveness of methadone maintenance treatment 3. Moderators of treatment outcome. In: Ward J, Mattick RP, Hall W, eds. Opioid maintenance treatment and other opioid replacement therapies. London: Harwood Academic Publishers, 1998:75-89.
36. Epstein DH, Preston KL. Does cannabis use predict poor outcome for heroin dependent patients on maintenance treatment? Past findings and more evidence against. Addiction 2003;98:269-79.
37. Richter KP, Ahluwalia JS. A case for addressing cigarette use in methadone and other opioid treatment programmes. J Addict Dis 2000;19:35-52.
38. Scott KM, Sarfati D, Tobias MI, Haslett SJ. A challenge to the cross-cultural validity of the SF-36 health survey: factor structure in Maori, Pacific and New Zealand European ethnic groups. Soc Sci Med 2000;51:1655-64.